|
|
News Breaks
|
November 3, 2009
|
| 07:17 EDT |  | ARWR |
| theflyonthewall.com: | ArrowHead Research CFO provides update on the company situation | | Arrowhead Research Corp.'s President and CFO, Christopher Anzalone, issued a letter to shareholders explaining that since he joined the company there has been considerable progress and that "Arrowhead is now at an inflection point based on four primary factors that have the potential to drive significant shareholder value: (1) Unidym is on the brink of breaking into some of its target markets; (2) Calando is at an advanced point in its siRNA clinical trial and we are seeing some exciting results; (3) our restructuring is largely complete and we are now a more flexible and cost efficient company; and (4) amid our aggressive cost-cutting initiatives and increased focus on near-term revenue, we have retained the means to capitalize on longer-term growth opportunities". :theflyonthewall.com |
|
|
News For ARWR From The Last 14 Days Check below for free stories on ARWR the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
